DanioLabs Ltd. was established in October 2001 to develop new drugs for neuro-ophthalmologic disorders. Frustrated at the lack of effective treatments available in these areas, the company's founder set about using zebrafish models of human disease to identify both novel drug targets and effective new drugs. Zebrafish can be manipulated to provide particularly good models of a number of human diseases, including CNS, ophthalmologic, digestive and cardiovascular system disorders.
Paul Goldsmith, PhD, and his co-founders established DanioLabs Ltd. in October 2001 to develop new drugs for neuro-ophthalmologic disorders. Frustrated at the lack of effective treatments available in these areas, neurologist Goldsmith set about using zebrafish models of human disease to identify both novel drug targets and effective new drugs.
Zebrafish—tiny vertebrates that in their embryonic and larval stages can be grown in as little as 50 microlitres of fluid—have...
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.
S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
